Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-3031 in relapsed or refractory solid tumors
NCT04809012Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of danburstotug in solid tumor, sponsored by Sorrento Therapeutics. Planned start Jun 2021; status: withdrawn.
02
Drugs
danburstotug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04809012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809012.